Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
Date:2/12/2013

lopment and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA in November 2012.  Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/31/2014)... 2014 2014 Market Research ... professional and in-depth research report on the ... information, including Polyacrylamide definition, classification, application, and ... overview. This research covers the international market ... global industry analysis covering macroeconomic environment & ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... SyntheMed, Inc. ("the Company") (OTCBB: SYMD; Pink Sheets: ... on the treatment of diseases characterized by organ-specific cell damage, ... 2011.  The Company changed its name to "Pathfinder Cell Therapy, ... OTC Bulletin Board, changing to a new trading symbol shortly. ...
... 2011 Omeros Corporation (NASDAQ: OMER ... developing and commercializing products targeting inflammation, coagulopathies and ... that Gregory A. Demopulos, M.D., chairman and chief ... Rodman and Renshaw 13th Annual Healthcare Conference taking ...
... The inaugural  European Neurotech Investing ... It features keynotes on the state of the European neurotech ... presentations on next generation treatments emerging in the EU for ... Alzheimer , s, addiction, depression, schizophrenia, Parkinson ...
Cached Biology Technology:Pathfinder, LLC and SyntheMed, Inc. Complete Merger 2Pathfinder, LLC and SyntheMed, Inc. Complete Merger 3High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 3
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... rise of the Tibetan plateau -- the largest topographic ... for both its profound effect on climate and its ... GSA Bulletin , Katharine Huntington and colleagues employ ... using modern and fossil snail shells to investigate the ... , Views range widely on the timing of ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... Massey Cancer Center studying the interaction between the ... gamma as one of the signaling proteins involved ... researchers develop tailored vaccines and other immunotherapeutic strategies ... the manipulation of the immune system ?by introducing ...
... M.D. and Ami Klin are part of a global research ... region of a chromosome that may lead to autism in ... Genetics and also will be published in the journal’s March ... scan. Over 120 scientists from over 50 institutions who formed ...
... cause of high blood pressure lies within the brain, and ... by scientists at the University of Bristol, UK, and is ... Waki, working in a research group led by Professor Julian ... (junctional adhesion molecule-1), which is located in the walls of ...
Cached Biology News:Mechanisms involved with tumor relapse identified 2Autism gene identified by researchers at Yale working with a global research consortium 2Blame the brain for high blood pressure 2
... IMPACT (Intein Mediated Purification with an ... activity of engineered protein splicing elements (termed ... single affinity column (1-4) (Figures 1 and ... protein fusion systems by its ability to ...
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides ... C2C12 myoblasts into mature skeletal myotubes. ... kit is a valuable tool in ... and in developing strategies for muscle ...
... Detection Assay is an anchorage-independent growth assay ... most stringent assay for detecting malignant transformation ... (pre-treated with carcinogens or carcinogen inhibitors) are ... medium for 21-28 days. Following this ...
Biology Products: